Skip to main content
. Author manuscript; available in PMC: 2024 Jul 15.
Published in final edited form as: Lancet. 2023 Jun 5;402(10397):185–195. doi: 10.1016/S0140-6736(23)00922-4

Figure 2. Progression-Free Survival Per Central Review.

Figure 2.

Figure 2.

Kaplan-Meier estimates of progression-free survival as assessed by blinded central review board in the intention-to-treat population (A) and in key subgroups (B). HR values in the subgroup analysis were unstratified. CI denotes confidence interval, HR, hazard ratio, ICI immune checkpoint inhibitor, IMDC International Metastatic Renal Cell Carcinoma Database Consortium, TKI tyrosine kinase inhibitor, VEGF vascular endothelial growth factor.